National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area.

Autor:	Loutet MG; National Infection Service, Public Health England, London, UK mirandagloutet@gmail.com., Burman M; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK.; Dept of Respiratory Medicine, Barts Health NHS Trust, London, UK., Jayasekera N; Dept of Respiratory Medicine, Barts Health NHS Trust, London, UK., Trathen D; Newham Clinical Commissioning Group, London, UK., Dart S; Dept of Respiratory Medicine, Barts Health NHS Trust, London, UK., Kunst H; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK.; Dept of Respiratory Medicine, Barts Health NHS Trust, London, UK., Zenner D; National Infection Service, Public Health England, London, UK.; Institute for Global Health, University College London, London, UK.; National Institute for Health Research Health Protection Research Unit in Respiratory Infections, Imperial College London, London, UK.
Jazyk:	angličtina
Zdroj:	The European respiratory journal [Eur Respir J] 2018 Jan 11; Vol. 51 (1). Date of Electronic Publication: 2018 Jan 11 (Print Publication: 2018).
DOI:	10.1183/13993003.01226-2017
Abstrakt:	Latent tuberculosis infection (LTBI) screening is an important intervention for tuberculosis (TB) elimination in low-incidence countries and is, therefore, a key component of England's TB control strategy. This study describes outcomes from a LTBI screening programme in a high-incidence area to inform national LTBI screening in England and other low-incidence countries.We conducted a retrospective cohort study of LTBI screening among eligible migrants (from high-incidence countries and entered the UK within the last 5 years), who were identified at primary-care clinics in Newham, London between August 2014 and August 2015. Multivariable logistic regression was used to identify factors associated with LTBI testing uptake, interferon-γ release assay (IGRA) positivity and treatment uptake.40% of individuals offered LTBI screening received an IGRA test. The majority of individuals tested were 16-35 years old, male and born in India, Bangladesh or Pakistan. Country of birth, smoking status and co-morbidities were associated with LTBI testing uptake. IGRA positivity was 32% among those tested and was significantly associated with country of birth, age, sex and co-morbidities.This study identifies factors associated with screening uptake, IGRA positivity and treatment uptake, and improves understanding of groups that should be supported to increase acceptability of LTBI testing and treatment in the community. Competing Interests: Conflict of interest: None declared. (Copyright ©ERS 2018.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu